Protecting Children from Chemical and Surgical Mutilation

Defines chemical and surgical mutilation of children as use of puberty blockers, sex hormones, or surgical procedures to align physical appearance with identity different from sex.

Agencies shall rescind policies relying on World Professional Association for Transgender Health guidance, and HHS shall publish a literature review on best practices for children with gender dysphoria.

Agencies providing research or education grants to medical institutions must ensure institutions receiving federal grants end chemical and surgical mutilation of children.

HHS must take action to end gender-affirming care in Medicare and Medicaid, withdraw 2022 guidance on gender-affirming care, and protect whistleblowers reporting compliance violations.

Department of Defense must exclude gender-affirming care and surgery from TRICARE coverage for minors and amend the provider handbook.

Office of Personnel Management must exclude pediatric transgender surgeries and hormone treatments from Federal Employee Health Benefits and Postal Service Health Benefits.

Attorney General shall prioritize enforcement against female genital mutilation, convene state attorneys general on coordination, and pursue private right of action legislation for harmed children.

Within 60 days, agency heads must report progress implementing this order to the Assistant to the President for Domestic Policy.

Standard severability clause: if a court strikes any provision, the rest of the order stands.

Standard boilerplate: preserves existing agency authority, conditions the order on appropriations, and creates no enforceable private rights.